RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hyloris Pharmaceuticals Stock

Hyloris Pharmaceuticals Equity 2024

Hyloris Pharmaceuticals Equity

39.07 M EUR

Ticker

HYL.BR

ISIN

BE0974363955

WKN

A2P7Y0

In 2024, Hyloris Pharmaceuticals's equity was 39.07 M EUR, a -27.53% increase from the 53.91 M EUR equity in the previous year.

Hyloris Pharmaceuticals Aktienanalyse

What does Hyloris Pharmaceuticals do?

Hyloris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Hyloris Pharmaceuticals's Equity

Hyloris Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Hyloris Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Hyloris Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Hyloris Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Hyloris Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Hyloris Pharmaceuticals stock

What is the equity of Hyloris Pharmaceuticals this year?

Hyloris Pharmaceuticals has equity of 39.07 M EUR this year.

What was the equity of Hyloris Pharmaceuticals compared to the previous year?

The equity of Hyloris Pharmaceuticals has increased/decreased by -27.53% decreased compared to the previous year.

What impact does a high equity have on investors of Hyloris Pharmaceuticals?

A high equity is advantageous for investors of Hyloris Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Hyloris Pharmaceuticals?

A low equity can be a risk for investors of Hyloris Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Hyloris Pharmaceuticals affect the company?

An increase in equity of Hyloris Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Hyloris Pharmaceuticals affect the company?

A reduction in equity of Hyloris Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Hyloris Pharmaceuticals?

Some factors that can affect the equity of Hyloris Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Hyloris Pharmaceuticals so important for investors?

The equity of Hyloris Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Hyloris Pharmaceuticals take to change the equity?

To change equity, Hyloris Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Hyloris Pharmaceuticals pay?

Over the past 12 months, Hyloris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hyloris Pharmaceuticals is expected to pay a dividend of 0 EUR.

What is the dividend yield of Hyloris Pharmaceuticals?

The current dividend yield of Hyloris Pharmaceuticals is .

When does Hyloris Pharmaceuticals pay dividends?

Hyloris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hyloris Pharmaceuticals?

Hyloris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hyloris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hyloris Pharmaceuticals located?

Hyloris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hyloris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hyloris Pharmaceuticals from 11/5/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Hyloris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Hyloris Pharmaceuticals in the year 2023?

In the year 2023, Hyloris Pharmaceuticals distributed 0 EUR as dividends.

In which currency does Hyloris Pharmaceuticals pay out the dividend?

The dividends of Hyloris Pharmaceuticals are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hyloris Pharmaceuticals

Our stock analysis for Hyloris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hyloris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.